drugset / Trial / NCT04839393
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
Non-randomizedSequentialOpen-labelBasic science
Summary
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants. Part B will evaluate the effect of PF-06882961 on the PK of PF-06865571, as well as the effect of PF-06865571 on the PK of PF-06882961 in overweight adults or adults with obesity who are otherwise healthy.
Timeline
- Start
- 2021-04-05
- Primary completion
- 2021-10-10
- Completion
- 2021-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danuglipron | Small molecule | 20 mg | — |
| Subject | Danuglipron | Small molecule | 200 mg | — |
| Subject | PF-06865571 | Small molecule | 300 mg | — |
Indications
No indication recorded.